Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06032962
Other study ID # MeirMedicalCenter
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 1, 2018
Est. completion date February 28, 2023

Study information

Verified date September 2023
Source Meir Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this study is to evaluate patient's compliance for opportunistic salpingectomy (OS) and procedure feasibility in non gynecological abdominal surgeries


Description:

Patients who are candidate for non-gynecological abdominal surgery, are offered OS. If agree, a general surgeon perform the procedure during the planned abdominal surgery


Recruitment information / eligibility

Status Completed
Enrollment 42
Est. completion date February 28, 2023
Est. primary completion date December 31, 2022
Accepts healthy volunteers No
Gender Female
Age group 40 Years and older
Eligibility Inclusion Criteria: - Women who were candidates for non-gynecological abdominal surgery - Aged 45 or older, or aged 40 or older with a desire for bilateral salpingectomy Exclusion Criteria: - Pregnant women - Candidates for urgent surgery

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
salpingectomy
surgical removal of the fallopian tubes

Locations

Country Name City State
Israel Meir medical center Kfar Saba

Sponsors (1)

Lead Sponsor Collaborator
Dana Josephy

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary patients willing for salpingectomy The number of patients that will agree for salpingectomy day of enrollment
Primary patients undergoing salpingectomy The number of patients that will undergo salpingectomy from enrollment and up to 6 weeks
Primary length of salpingectomy the length (in minutes) of salpingectomy within surgery
Primary surgical complications complications during or after salpingectomy up to 30 days from surgery
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03480776 - ASA in Prevention of Ovarian Cancer (STICs and STONEs) Phase 2